<DOC>
	<DOCNO>NCT00808223</DOCNO>
	<brief_summary>To establish safety alefacept administered adolescent subject moderate severe psoriasis .</brief_summary>
	<brief_title>Safety Pharmacokinetics ( PK ) Alefacept Adolescent Subjects With Moderate Severe Psoriasis</brief_title>
	<detailed_description>A plan interim analysis conduct evaluate safety pharmacokinetics follow Week 4 evaluation approximately first 12 subject . A dose adjustment may implement base result . A preliminary review Week 4 pharmacokinetics first 6 subject occur monitor exposure . If dose adjustment require , pharmacokinetics repeat first 12 subject enrol new dose ( subject 13-24 ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject moderate severe chronic plaque psoriasis involve least 10 % great body surface area Subject candidate systemic treatment phototherapy Subject good health alefacept contraindicate Subject must absolute total CD4+ lymphocyte count within normal range screen Female subject child bear potential negative pregnancy test prior first dose alefacept agree practice effective contraception study Subject must predosing laboratory finding without clinically significant abnormal value hematocrit , hemoglobin , platelet , white blood count differential , serum creatinine , bilirubin , ALT , AST prothrombin . Subject must complete standard childhood immunization least 12 week prior first dose Subject meet medication washout requirement agrees follow medication restriction study Subject agrees comply study requirement agree come clinic require study visit Subject primary dermatological diagnosis psoriasis plaque psoriasis Subject know hypersensitivity alefacept excipient study medication Subject serious local infection systemic infection within 12 week prior first dose study drug Subject fever ( body temperature ≥ 38°C [ &gt; 37°C site Latvia ] ) symptomatic viral bacterial infection ( include upper respiratory tract infection ) within 1 week prior first dose study drug Subject know positive HIV antibody Subject history chronic serious infection include hepatic disease positive result serology test hepatitis A antibody IgM , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) antibody , Europe , tubercle bacillus ( TB ) Screening Subject history evidence tuberculosis base serology positive PPD skin test Screening Subject treatment immunosuppressant agent within 12 week , antibody immunoglobulin within 24 week , investigational drug approve therapy investigational use within 8 week prior first dose study drug Subject six herpes simplex virus ( HSV ) breakouts per year currently outbreak outbreak within last 24 week Subject history malignancy ( nonmelanoma skin cancer ) Subject chronic condition well control Subject pregnant nursing Subject history severe allergic anaphylactic reaction</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>alefacept</keyword>
	<keyword>adolescent</keyword>
	<keyword>psoriasis</keyword>
</DOC>